Brief: Liquidia Provides Update On Hatch-Waxman Litigation Tied To ‘327 Patent
BRIEF-Liquidia Provides Update On Hatch-Waxman Litigation Tied To ‘327 Patent Sept 30 (Reuters) - Liquidia Corporation LQDA.O:
LIQUIDIA PROVIDES UPDATE ON HATCH-WAXMAN LITIGATION TIED TO ‘327 PATENT
LIQUIDIA CORPORATION - DISTRICT COURT RULES TWO CLAIMS AGAINST LIQUIDIA VALID AND INFRINGED
LIQUIDIA CORPORATION - REMAINING ASSERTED CLAIMS OF '327 PATENT AGAINST LIQUIDIA FOUND INVALID
LIQUIDIA CORPORATION - PARTIES TO SUBMIT FORM OF JUDGMENT SPECIFYING REMEDY WITHIN ONE WEEK
LIQUIDIA CORPORATION - UTHR REQUESTS INJUNCTIVE RELIEF TO RESTRICT YUTREPIA MARKET AVAILABILITY
LIQUIDIA CORPORATION - CLAIMS 1 AND 14 OF '327 PATENT VALID AND INFRINGED BY LIQUIDIA
LIQUIDIA CORPORATION: "RESPECTFULLY DISAGREE WITH COURT'S DECISION REGARDING CLAIMS 1 AND 14"
Source text: ID:nGNX147vb4
Further company coverage: LQDA.O
(Reporting by Zakia Mariyam)
((Zakia.Mariyam@thomsonreuters.com;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug